Quintrio
Home

HOSPITAL & MEDICAL SERVICE PLANS

The Cigna Group

CI

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.

Last trade $294.10
Day change -$6.065 (-2.02%)
Day range $293.62 – $299.86
Volume 758,281
Market cap $79.09B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$79.09B
Price / earnings
13.2×
Price / book
1.82×
Price / sales
0.28×
EV / sales
0.36×
EV / EBITDA
8.99×

Profitability

Earnings per share
$22.73
Return on assets
3.8%
Return on equity
13.81%
Dividend yield
2.06%

Liquidity and leverage

Debt / equity
0.72×
Current ratio
0.84×
Quick ratio
0.74×
Cash ratio
0.11×

Cash flow

Price / cash flow
8.39×
Price / free cash flow
9.57×
Free cash flow
$8.27B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$73.4B$71.4B$68.29B$72.13B$69.52B$66.94B$65.26B$65.37B
Cost of revenue$67.09B$65.13B$62.02B$66.06B$63.37B$61.02B$58.9B$59.19B
Gross profit$6.31B$6.26B$6.27B$6.08B$6.14B$5.93B$6.37B$6.19B
Selling, general and administrative$3.61B$3.47B$3.72B$3.61B$3.36B$3.43B$4.21B$3.87B
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$4.2B$3.86B$4.11B$4.07B$3.8B$3.86B$4.64B$4.29B
Operating income$2.11B$2.4B$2.16B$2.01B$2.35B$2.07B$1.73B$1.9B
Interest expense-$333M-$356M-$357M$1.05B-$347M-$337M-$362M$1.07B
Income before taxes$2.1B$2.26B$2.27B$1.82B$2.3B$2.02B$1.65B$2.01B
Income taxes$401M$382M$409M$543M$322M$389M$239M$473M
Net income$1.7B$1.88B$1.86B$1.27B$1.97B$1.63B$1.41B$1.54B
Net income attributable to common shareholders$1.44B$1.66B$1.65B$1.23B$1.87B$1.53B$1.32B$1.42B
EBITDA$2.98B$3.06B$2.81B$2.73B$3.04B$2.75B$2.41B$2.54B
Basic earnings per share$5.49$6.31$6.30$4.67$7.02$5.76$4.88$5.18
Diluted earnings per share$5.47$6.29$6.26$4.65$6.98$5.71$4.85$5.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Can UNH's Optum Rx Sustain Profit Growth as Prescription Volumes Fall?

UnitedHealth Group's Optum Rx segment increased operating earnings by 10.9% to $1.72 billion in Q3 2026 despite a 5.1% decline in adjusted prescriptions, driven by biosimilar adoption and operational efficiencies. However, membership losses and declining prescription volumes pose sustainability challenges for future growth. Specialty pharmacy volumes grew 2.6%, offering some offset to overall volume pressures.

Zacks Investment Research

Can CVS Health's 2028 Split Unlock Value Despite Execution Risks?

CVS Health announced plans to separate into two independent publicly traded companies by mid-2028: one retaining Aetna, Caremark, and care operations, and another housing retail pharmacies and MinuteClinic. The split aims to improve capital allocation and operating flexibility, though it carries execution risks, restructuring costs, and potential dis-synergies during the transition period.

Zacks Investment Research

Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist?

CVS Health is entering a more constructive earnings phase as Aetna's medical benefit ratio improves, pharmacy operating income rises 10.6%, and operating cash flow reaches $15.32 billion. However, persistent pressure from pharmacy benefit management, medical membership declines, and reimbursement headwinds keep execution risk elevated through 2027.

Zacks Investment Research

Here's Why Cigna (CI) is a Strong Momentum Stock

Cigna Corporation (CI) receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of A. The stock has shown strong momentum with a 4.3% gain over the past four weeks. Nine analysts revised earnings estimates higher in the last 60 days, with the consensus estimate increasing to $30.68 per share and an average earnings surprise of +3.6%.

Zacks Investment Research

Cigna Q3 Earnings Top Estimates on Cigna Healthcare Strength

Cigna Group reported Q3 2026 adjusted EPS of $7.98, beating estimates by 7%, with revenues growing 6.1% to $73.8B. Cigna Healthcare segment showed strong performance with 8.9% revenue growth and 14.9% operating income growth. The company raised its 2026 adjusted EPS outlook to at least $30.60 and Cigna Healthcare's operating income target to $4.6B. However, Evernorth Health Services missed revenue estimates and Pharmacy Benefit Services contributed less than expected.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $1.56 per share
Declared
Oct 28, 2026
Ex-dividend
Dec 3, 2026
Pay date
Dec 17, 2026
Ex-dividendAmount / sharePay dateType
Sep 8, 2026$1.56Sep 23, 2026recurring
Jun 4, 2026$1.56Jun 18, 2026recurring
Mar 5, 2026$1.56Mar 19, 2026recurring
Dec 4, 2025$1.51Dec 18, 2025recurring
Sep 4, 2025$1.51Sep 18, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 5, 20073-for-1forward split